Expertise in
30
conditions

Dr. Pradeep K. Bekal

Gastroenterology
2925 Vernon Place, Suite 100, 
Cincinnati, OH 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
30
conditions
2925 Vernon Place, Suite 100, 
Cincinnati, OH 

Overview

Pradeep Bekal is a Gastroenterologist practicing medicine in Cincinnati, Ohio.

Dr. Bekal is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Familial Adenomatous Polyposis, Gardner Syndrome, Turcot Syndrome, Colonoscopy, and Endoscopy.

Dr. Bekal is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, participating in 10 clinical trials. Dr. Bekal is currently accepting new patients.

Specialties

Gastroenterology

Licenses

Internal Medicine in OH

Board Certifications

American Board Of Internal Medicine

Fellowships

Medical College Of Pennsylvania & Hahnemann Univer, Gastroenterology, 1996
Brooklyn Hospital-Caledonian Hosp., Gastroenterology, 1995

Hospital Affiliations

Christ Hospital
University Of Cincinnati Medical Center, LLC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

Gastro Health
2925 Vernon Place, Suite 100, Cincinnati, OH 45219

Additional Areas of Focus

Dr. Bekal has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

3-Arm Randomized Placebo Controlled Double Blind Phase 3 Study to Evaluate Safety and Efficacy of Once-Daily and Twice-Daily Hydrocortisone Acetate 90 mg Suppository Administered With a Sephure Suppository Applicator in Subjects With Ulcerative Colitis of the Rectum
3-Arm Randomized Placebo Controlled Double Blind Phase 3 Study to Evaluate Safety and Efficacy of Once-Daily and Twice-Daily Hydrocortisone Acetate 90 mg Suppository Administered With a Sephure Suppository Applicator in Subjects With Ulcerative Colitis of the Rectum
Enrollment Status: Completed
Publish Date: August 06, 2026
Intervention Type: Combination product
Study Drug: Hydrocortisone acetate suppository administered with Sephure applicator
Study Phase: Phase 3
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Other
Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening BLUE-C
Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening BLUE-C
Enrollment Status: Completed
Publish Date: September 01, 2023
Intervention Type: Procedure, Diagnostic test
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
Enrollment Status: Terminated
Publish Date: April 29, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
View 9 Less Clinical Trials
Similar Doctors
Expertise in
13
conditions
Dr. Kenneth E. Sherman
Gastroenterology
Expertise in
13
conditions
Dr. Kenneth E. Sherman
Gastroenterology
Referral may be required

Thoma & Sutton EyeCare Professionals LLC

222 Piedmont Ave, 
Cincinnati, OH 
 (0.3 miles away)
513-475-7505
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kenneth Sherman is a Gastroenterologist practicing medicine in Cincinnati, Ohio. Dr. Sherman is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Hepatitis, Cirrhosis, Hepatitis C, Liver Transplant, and Kidney Transplant. Dr. Sherman is currently accepting new patients.

Expertise in
32
conditions
Dr. Andrew Ofosu
Gastroenterology
Expertise in
32
conditions
Dr. Andrew Ofosu
Gastroenterology
Referral may be required

Thoma & Sutton EyeCare Professionals LLC

222 Piedmont Ave, 
Cincinnati, OH 
 (0.3 miles away)
513-475-7505
Languages Spoken:
English, Igbo
See accepted insurances
Accepting New Patients

Andrew Ofosu is a Gastroenterologist practicing medicine in Cincinnati, Ohio. Dr. Ofosu is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Jaundice, Choledocholithiasis, Gastrointestinal Bleeding, Endoscopy, and Stent Placement. Dr. Ofosu is currently accepting new patients.

Expertise in
51
conditions
Dr. Said I. Nabhan
Gastroenterology
Expertise in
51
conditions
Dr. Said I. Nabhan
Gastroenterology
Referral may be required
Before you request

Cincinnati GI

4805 Montgomery Road, Suite 160, 
Cincinnati, OH 
 (3.3 miles away)
513-721-5300
Languages Spoken:
English, Arabic, Arabic - Jordanian, French
See accepted insurances
Accepting New Patients

Said Nabhan is a Gastroenterologist practicing medicine in Cincinnati, Ohio. Dr. Nabhan is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Lower Esophageal Ring, Benign Esophageal Stricture, Colitis, Endoscopy, and Gastrectomy. Dr. Nabhan is board certified in American Board Of Internal Medicine, Gastroenterology - 1997, American Board Of Internal Medicine - 1994, and American Board Of Internal Medicine. Dr. Nabhan is currently accepting new patients.

Frequently Asked Questions about Dr. Pradeep K. Bekal

How do I make an appointment with Dr. Pradeep K. Bekal?

You can book an appointment with Dr. Pradeep K. Bekal by calling their office at 513-751-6667. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Pradeep K. Bekal a top-rated expert for Familial Adenomatous Polyposis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Pradeep K. Bekal is classified as an Distinguished expert for Familial Adenomatous Polyposis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Pradeep K. Bekal specialize in?

While Dr. Pradeep K. Bekal is a Gastroenterology, they have specific expertise in Familial Adenomatous Polyposis, Gardner Syndrome, and Turcot Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Pradeep K. Bekal accept my insurance?

Dr. Pradeep K. Bekal accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 513-751-6667 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bekal's expertise for a condition
ConditionClose
    View All 27 Advanced Conditions
    View All 71 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile